tetano
Editor, Senior Moderator
BMC Infect Dis
. 2024 Sep 12;24(1):959.
doi: 10.1186/s12879-024-09891-z. Longevity of hybrid immunity against SARS-CoV-2 in adults vaccinated with an adenovirus-based COVID-19 vaccine
Memory Mvula[SUP] 1 [/SUP], Fatima Mtonga[SUP] 1 [/SUP], Jonathan Mandolo[SUP] 1 2 [/SUP], Chisomo Jowati[SUP] 1 [/SUP], Alice Kalirani[SUP] 1 [/SUP], Precious Chigamba[SUP] 1 [/SUP], Edwin Lisimba[SUP] 1 [/SUP], Ndaona Mitole[SUP] 1 [/SUP], Marah G Chibwana[SUP] 1 3 [/SUP], Kondwani C Jambo[SUP] 4 5 [/SUP]
Affiliations
Background: Hybrid immunity provides better protection against COVID-19 than vaccination or prior natural infection alone. It induces high magnitude and broadly cross-reactive neutralising anti-Spike IgG antibodies. However, it is not clear how long these potent antibodies last, especially in the context of adenovirus-based COVID-19 vaccines.
Methods: We conducted a longitudinal cohort study and enrolled 20 adults who had received an adenovirus-based COVID-19 vaccine before a laboratory-confirmed SARS-CoV-2 infection. We followed up the study participants for 390 days post the initial breakthrough infection. We assessed the longevity and cross-reactive breadth of serum antibodies against SARS-CoV-2 variants of concern (VOCs), including Omicron.
Results: The binding anti-Spike IgG antibodies remained within the reported putative levels for at least 360 days and were cross-neutralising against Beta, Gamma, Delta, and Omicron. During the follow up period, a median of one SARS-CoV-2 re-infection event was observed across the cohort, but none resulted in severe COVID-19. Moreover, the re-exposure events were associated with augmented anti-Spike and anti-RBD IgG antibody titres.
Conclusions: This study confirms that hybrid immunity provides durable broadly cross-reactive antibody immunity against SARS-CoV-2 variants of concern for at least a year (360 days), and that it is further augment by SARS-CoV-2 re-exposure.
Keywords: Breakthrough infection; Hybrid immunity; Longevity; SARS-CoV-2.
. 2024 Sep 12;24(1):959.
doi: 10.1186/s12879-024-09891-z. Longevity of hybrid immunity against SARS-CoV-2 in adults vaccinated with an adenovirus-based COVID-19 vaccine
Memory Mvula[SUP] 1 [/SUP], Fatima Mtonga[SUP] 1 [/SUP], Jonathan Mandolo[SUP] 1 2 [/SUP], Chisomo Jowati[SUP] 1 [/SUP], Alice Kalirani[SUP] 1 [/SUP], Precious Chigamba[SUP] 1 [/SUP], Edwin Lisimba[SUP] 1 [/SUP], Ndaona Mitole[SUP] 1 [/SUP], Marah G Chibwana[SUP] 1 3 [/SUP], Kondwani C Jambo[SUP] 4 5 [/SUP]
Affiliations
- PMID: 39266969
- PMCID: PMC11391831
- DOI: 10.1186/s12879-024-09891-z
Background: Hybrid immunity provides better protection against COVID-19 than vaccination or prior natural infection alone. It induces high magnitude and broadly cross-reactive neutralising anti-Spike IgG antibodies. However, it is not clear how long these potent antibodies last, especially in the context of adenovirus-based COVID-19 vaccines.
Methods: We conducted a longitudinal cohort study and enrolled 20 adults who had received an adenovirus-based COVID-19 vaccine before a laboratory-confirmed SARS-CoV-2 infection. We followed up the study participants for 390 days post the initial breakthrough infection. We assessed the longevity and cross-reactive breadth of serum antibodies against SARS-CoV-2 variants of concern (VOCs), including Omicron.
Results: The binding anti-Spike IgG antibodies remained within the reported putative levels for at least 360 days and were cross-neutralising against Beta, Gamma, Delta, and Omicron. During the follow up period, a median of one SARS-CoV-2 re-infection event was observed across the cohort, but none resulted in severe COVID-19. Moreover, the re-exposure events were associated with augmented anti-Spike and anti-RBD IgG antibody titres.
Conclusions: This study confirms that hybrid immunity provides durable broadly cross-reactive antibody immunity against SARS-CoV-2 variants of concern for at least a year (360 days), and that it is further augment by SARS-CoV-2 re-exposure.
Keywords: Breakthrough infection; Hybrid immunity; Longevity; SARS-CoV-2.